Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Zak Mir takes a technical perspective on some of the most followed small caps in London. Today’s selection includes Beowulf Mining, Bezant Resources, Chill Brands Group, Eurasia Mining, Gunsynd, Myhealthchecked,
Cambridge, UK, 30 July 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases.
Completed Covid-19 Research Project Delivers Encouraging Results
Subscription to raise £900,000 to progress proprietary TYK2/JAK1 programmes through final stages of preclinical development
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Sareum Notes SRA737 Combination Data to be Presented at the AACR Annual Meeting
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.